Bilal A. Siddiqui
YOU?
Author Swipe
View article: Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance Open
Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. Transforming growth factor-β (TGFβ) induces the expression of this plasma membrane protein specifically in aggressive and trea…
View article: Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Purpose:Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity of tarlatamab, a bispecific T-c…
View article: Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Figure S2. Study design.
View article: Supplementary Table S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Table S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Table S1. Representativeness of study participants.
View article: Supplementary Figure S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Figure S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Figure S1. Patient disposition.
View article: Supplementary Table S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Table S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Table S2. Common (≥20%) treatment-emergent adverse events.
View article: Supplementary Figure S3 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Figure S3 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Figure S3. Scatter plot for treatment response as a relationship between pretreatment T cells and DLL3 expression.
View article: Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity of tarlatamab, a bispecific T-…
View article: Calcific uremic arteriolopathy with penile involvement post-kidney transplant
Calcific uremic arteriolopathy with penile involvement post-kidney transplant Open
Calcific uremic arteriolopathy (calciphylaxis) is a rare, painful condition in ESRD patients causing skin lesions and tissue ischemia. While typically affecting proximal areas, distal sites, including the penis, can also be involved. We pr…
View article: Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT)
Hemophagocytic Lymphohistiocytosis (HLH) Following Immune Checkpoint Therapy (ICT) Open
In the past decade, the use of immune checkpoint therapy (ICT) has increased across many malignancies, including metastatic renal cell carcinoma as an option for frontline and subsequent lines of therapy. Despite the many therapeutic benef…
View article: Key Regulatory Elements of the TGFβ-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types
Key Regulatory Elements of the TGFβ-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types Open
Transforming growth factor-beta (TGFβ) has dual roles in cancer, initially suppressing tumors but later promoting metastasis and immune evasion. Efforts to inhibit TGFβ have been largely unsuccessful due to significant toxicity and indiscr…
View article: Body composition in recurrent prostate cancer and the role of steroidogenic genotype
Body composition in recurrent prostate cancer and the role of steroidogenic genotype Open
Hormone therapy (HT) to treat prostate cancer is reported to cause adverse changes in body composition. Clinically, interpatient body composition changes are heterogeneous, but the biological and clinical determinants of body composition t…
View article: Supplementary Figure 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Clinical characteristics of patients with confirmed toxicities
View article: Supplementary Figure 18 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 18 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Comparison of the transcriptional programs between samples from patients with myasthenia gravis (MG) versus patients without MG
View article: Supplementary Figure 4 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 4 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Analysis of CD45- subpopulations in cardiac muscle
View article: Supplementary Figure 17 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 17 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Cell-cell communication analysis from endothelial cells and myeloid cells to cytotoxic T cells in myositis
View article: Supplementary Figure 16 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 16 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Cell-cell communication analysis from fibroblasts, endothelial cells, and myeloid cells to cytotoxic T cells in myocarditis
View article: Supplementary Figure 8 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 8 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Single cell TCR sequencing (scRNASeq) from patient cardiac and skeletal muscle tissue
View article: Supplementary Table 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Table 1 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Baseline Clinical Characteristics
View article: Supplementary Table 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Table 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Clinical characteristics of control patients
View article: Supplementary Figure 5 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 5 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Hierarchical clustering based on Euclidean distance of expression in CD45- cells
View article: Supplementary Figure 7 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 7 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Differentially expressed genes (DEGs) in Cytotoxic CD8+ T Cells
View article: Supplementary Figure 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis
Supplementary Figure 3 from Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis Open
Analysis of CD45- subpopulations in cardiac muscle